Icosagen is a research-driven contract research provider for biopharmaceutical and biotechnology industries that deftly adapts to market forces and current trends, and is always guided by the needs of its customers.
Icosagen offers custom-tailored services for recombinant protein production in mammalian cells, and antibody development. By using patented state-of-the-art technologies, we deliver high quality products to the biopharmaceutical and diagnostic companies. Our company's quality control and assurance system is ISO9001:2008 certified.
Icosagen offers a broad range of tailored services for the development and production of recombinant antibodies, including complex antibody formats.
Our customers benefit from our cost effective QMCF Expression Technology that is based on the replication, and stable maintenance of the expression vectors in CHO cells, in conjunction with specifically optimized culture conditions for the recombinant antibody production.
We can start either from antibody (or VH/VL) sequence information, hybridoma cells, or cDNA, and we deliver high quality material (purity >98%, endotoxin levels <0,1 EU/mg) together with elaborated project report containing detailed QC data and analysis.
Recombinant antibody production services includes the possibility to change antibody subtype or host specificity, and to generate various types of antibodies, such as human IgG1, IgG2, IgG4, mouse IgG1, IgG2a, IgG2b, IgG3, rat IgG1, IgG2a, rabbit IgG, chicken IgY, chimeric antibodies, antibody fragments, single chain molecules, bispecific antibodies (bi- scFV-Fc, DVD-Ig, Crossmabs), etc.
There are two options for recombinant antibody production by using QMCF Technology:
Transient production includes:
Stable production, including selection and cell bank generation:
Recombinant protein production service
Icosagen provides recombinant protein production services using proprietary CHO-based QMCF Technology in serum-free conditions. Customer benefits are a short production time and cost-efficiency.
We offer two options for protein production:
Transient production of recombinant proteins includes:
Stable production including selection and cell bank generation:
Production of VLP-s pseudotyped with membrane proteins
Expression of viral envelope or capsid proteins results in the self-assembly of virus-like particles (VLPs) that provide a great platform for the production of functional membrane proteins with native folding. This kind of pseudotyped VLPs could be used for different approaches, e.g. vaccine development, investigation of receptor functions, screening of antibodies, for immunization and also for purification of different membrane proteins.
Icosagen produces VLPs pseudotyped with membrane proteins, such as ion-channels, receptors, viral glycoproteins, etc. For the formation of VLPs, we use retroviral (HIV-1 or MLV) and filoviral (ebola) proteins. VLPs could be produced in 293 or CHO-based QMCF cell lines.
Icosagen provides a full service production of polyclonal antibodies in rabbit or chicken hosts. For immunization, KLH (or other carrier) conjugated peptides, recombinant proteins and other available immunogenes could be used. We recommend using recombinant proteins for immunization due to the stronger immune response and larger number of epitopes available when compared with peptide immunization.
Polyclonal antibody production service includes:
In the case of chicken (IgY) antibody generation, 2-3 immunizations will be performed within 30 days, and the required number of eggs will be collected. Antibody IgY fraction is extracted from egg yolk, followed by affinity purification.
For generation of rabbit polyclonal antibodies, 3-4 immunizations within 45 to 90 days are needed to develop a good immune response. Thereafter, serum is collected and antibodies are affinity purified.
For immunization, 0.5 - 3 mg of immunogenes per one test animal is needed. Additionally, approximately 5 mg of protein is needed for affinity purification.
Monoclonal antibody development service by mouse hybridoma technology
This service includes immunization of mice with immunogenes, following by hybridoma generation, screening and subcloning, antibody production in hybridoma cell culture, purification and characterization.
We develop antibodies against KLH (or other carrier) conjugated peptides, recombinant proteins, and other available immunogenes. We recommend the use of recombinant proteins due to stronger immune response and availability of larger number of epitopes when compared with peptide immunization.
Icosagen offers monoclonal antibody development from chicken and rabbits by using our proprietary HybriFree technology that is based on the VH/VL cloning from B-cells.
Development of monoclonal antibodies (MAbs) using HybriFree Technology is attractive for generation of immunomolecules from species other than mice. There are several technologies described for the development of recombinant monoclonal antibodies including phage display, single B-cell cloning, proteomics, NGS (Next Generation Sequencing) based etc. However, these all have drawbacks: using bacterial or yeast expression system in phage display, selected MAbs may not be functional; problems with robustness (single B-cell manipulations and/or sterile cultivation of B-cells) may occur; or expensive devices or patented technologies are needed.
We have worked out HybriFree Technology for the development of monoclonal antibodies from different species such as chicken and rabbits. It can also be used for cloning antibodies from existing hybridomas.
The process contains following steps:
The HybriFree Technology has several advantages:
Icosagen Technologies Inc. has not received any reviews.
Icosagen Technologies Inc. has not received any endorsements.